EMERYVILLE, Calif., December 4, 2024 – Slingshot Biosciences today announced the addition of Nimisha Srivastava, Ph.D. as Chief Operations Officer. Dr. Srivastava brings more than 20 years of experience in nanofluidics, synthetic biology technology development and operational scale-up, as well as a proven track record of building high-performing technical teams. Dr. Srivastava’s expertise in scaling disruptive […]

Emeryville, CA – November 6th, 2024 – Slingshot Biosciences, Inc. (Slingshot Biosciences), a leading biotechnology company revolutionizing the development of cell mimics for diagnostic and therapeutic applications, is excited to announce the appointment of Tiffany Salas-Morris as Chief Commercial Officer (CCO). In her new role, Tiffany will lead the company’s commercial strategy, focusing on accelerating […]

The Prolocor pFCG® test measures the expression of a specific protein on the platelet surface which this study demonstrates is a reliable prognostic tool to help assess the risk of thrombosis (a key cause of heart attack & stroke) and inform clinical decision making. This novel test is performed on fixed platelets and uses TruCytes™ […]

EMERYVILLE, Calif.–(BUSINESS WIRE)–In response to strong customer demand, Slingshot Biosciences is introducing a groundbreaking portfolio of products that will transform the landscape of analytical precision in cell therapy. Its first products in this category are aimed at solving quality control challenges that plague current cell therapy development and manufacturing processes. In the evolving field of […]

EMERYVILLE, Calif.–(BUSINESS WIRE)–Slingshot Biosciences Inc., a leader in the development of cell mimics for cell therapy, diagnostics, and rare disease research, is proud to announce the addition of Nicolas Barthelemy as its Executive Chair. “We have been working closely with Nicolas over the last two years and are excited to bring his experience, operational expertise, […]

Developing synthetic cells for a range of applications in diagnostics and therapeutics EMERYVILLE, Calif.–(BUSINESS WIRE)–Slingshot Biosciences, a biotechnology company building the world’s first on-demand synthetic cell platform for customizing cell and cell line mimics, today announced the closing of $11 million in a Series A3 financing. The investment was co-led by ARCH Venture Partners and Northpond Ventures, with […]

EMERYVILLE, Calif.–(BUSINESS WIRE)–SLINGSHOT BIOSCIENCES, INC. the developers of synthetic cells, today announced they have extended their distribution channel through a new agreement with Palex Medical, a company group dedicated to providing advanced solutions in the hospital and research sectors. The agreement entitles Palex Medical the rights to distribute and resell Slingshot Bio’s complete product line-up […]

EMERYVILLE, Calif.–(BUSINESS WIRE)–SLINGSHOT BIOSCIENCES, INC. the makers of synthetic cells that bring consistent precision and accurate control to replace inconsistent blood and tissue controls for use in flow cytometry and other biotech markets, today announced they have extended their distribution channel through a new agreement with Ozyme, a French company dedicated to the supply of […]

EMERYVILLE, Calif.–(BUSINESS WIRE)–SLINGSHOT BIOSCIENCES, INC. the makers of synthetic cells that bring consistent precision and accurate control to replace inconsistent blood and tissue controls for use in flow cytometry and other biotech markets, today announced they have extended their distribution channel through a new agreement with Kem-En-Tec Nordic A/S, Provider of Competent Bioscience products to […]

EMERYVILLE, Calif.–(BUSINESS WIRE)–SLINGSHOT BIOSCIENCES, INC. the makers of synthetic cells that bring consistent precision and accurate control to replace inconsistent blood and tissue controls for use in flow cytometry and other biotech markets, today announced they have extended their distribution channel through a new agreement with Cambridge Bioscience, a UK-based specialist distributor of life science […]

Building synthetic cells to broaden access to advanced diagnostics and therapeutics EMERYVILLE, Calif.–(BUSINESS WIRE)–Slingshot Biosciences, a biotechnology company building the world’s first on-demand synthetic cell platform, today announced the closing of $23 million in a Series A financing. The investment was led by Northpond Ventures, with participation from ARCH Venture Partners and Anterra Capital. The new funding will enable […]

Emeryville, CA (June 14, 2022) – SLINGSHOT BIOSCIENCES, INC. the makers of synthetic cells that bring consistent precision and accurate control to replace inconsistent blood and tissue controls for use in flow cytometry and other biotech markets, today announced they have extended their distribution channel through a new agreement with Almog Diagnostic, a private company […]